GSK3B and myotonic dystrophy type 1: Thus, the correction of GSK3β-CUGBP1 signaling in DM1 mouse models recovers not only muscle dysfunction (muscle weakness, myotonia, atrophy and myopathy), but might also reduce CNS pathology.